Stocktwits on MSN

REPL stock tracks best day ever: This analyst sees higher approval odds for Replimune’s melanoma after ‘overwhelmingly positive’ panel outcome

Cantor Fitzgerald upgraded Replimune to Overweight from Neutral without a price target ・The Adcom panel voted 10-3 in favor of RP1 ahead of the FDA’s official decision on Aug 2. ・The panel said the ...

REPL Stock Clocks Worst Day In Over 3 Months — New FDA Documents Leave Wall Street Awaiting Another Rejection For Cancer Drug

Shares of Replimune Group Inc (REPL) closed 38% lower on Tuesday, clocking its worst day since early April, after the U.S.
TechCrunch

Repl.it lets you program in your browser

No matter whether you are a seasoned programmer or you simply want to take your first steps in writing code, Repl.it wants to help you get from idea to result as fast as possible — without complicated ...

Why Is REPL Stock Soaring 127% After Hours Today?

Replimune announced a favorable outcome for its melanoma drug following a meeting of the FDA’s Cellular, Tissue and Gene ...
Seeking Alpha

Replimune: Multiple Shots On Goal But A High Risk Binary Approaches

In July 2025, REPL announced it had received a CRL for its biologics license application (BLA) for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma patients who were PD-1 ...